308.59
+21.07(+7.33%)
Currency In USD
| Previous Close | 287.52 |
| Open | 292 |
| Day High | 310.03 |
| Day Low | 292 |
| 52-Week High | 377.46 |
| 52-Week Low | 200.63 |
| Volume | 351,806 |
| Average Volume | 329,863 |
| Market Cap | 6.85B |
| PE | -17.31 |
| EPS | -17.83 |
| Moving Average 50 Days | 292.35 |
| Moving Average 200 Days | 298.39 |
| Change | 21.07 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $4,081.88 as of July 10, 2025 at a share price of $308.59. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $2,969.78 as of July 10, 2025 at a share price of $308.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
GlobeNewswire Inc.
Jun 20, 2025 10:30 AM GMT
Positive recommendation based on resmetirom’s favorable profile including positive results from the pivotal Phase 3 MAESTRO-NASH trialEuropean Commission decision expected in August 2025; if approved, resmetirom will be the first medication for peopl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jun 17, 2025 8:05 PM GMT
CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced tha
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40